SIPORE
LIVE

Serial Number

79245402

Owner

Sigrid Therapeutics AB

Attorney

Bradley L. Cohn

Filing Date

Jun 1, 2018

Add to watchlist:

No watchlists yet
View on USPTO

SIPORE Trademark

Serial Number: 79245402 • Registration: 5999045

SIPORE is a trademark filed by Sigrid Therapeutics AB on June 1, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Sigrid Therapeutics AB (5 trademarks)

Birger Jarlsgatan 57

Entity Type: 98

Trademark Details

Filing Date

June 1, 2018

Registration Date

March 3, 2020

Published for Opposition

December 17, 2019

Goods & Services

Dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; pharmaceuticals and natural remedies for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; nutritional supplements; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure

Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated devices and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 18, 2025 ADCH
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 3, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 2, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 29, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 24, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 8, 2020 FICS
FINAL DISPOSITION PROCESSED
Jul 8, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 3, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 3, 2020 R.PR
NOTIFICATION PROCESSED BY IB
Dec 20, 2019 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2019 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 4, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 4, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2019 NONP
ASSIGNED TO LIE
Nov 14, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 10, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 5, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 4, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 4, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 13, 2019 GNFN
FINAL REFUSAL E-MAILED
Jun 13, 2019 GNFR
FINAL REFUSAL WRITTEN
Jun 13, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2019 TROA
ATTORNEY REVIEW COMPLETED
Feb 8, 2019 ATRV
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Feb 7, 2019 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Feb 1, 2019 LIMG
REFUSAL PROCESSED BY IB
Dec 21, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 4, 2018 RFCS
REFUSAL PROCESSED BY MPU
Dec 4, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Nov 23, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 21, 2018 RFCR
NON-FINAL ACTION WRITTEN
Nov 20, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 19, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 19, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 15, 2018 REPR